ArticleBMC cancer2026
Interrelation between lncRNA HOTAIR and EZH2 expression and progression free survival during endocrine treatment in breast cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHOTAIR and EZH2 have been identified to interact and to play a role in breast cancer development. In this retrospective clinical cohort study, HOTAIR lncRNA and EZH2 mRNA expression levels were analyzed to assess their combined value as a predictive marker in breast cancer. PATIENTS AND
methodsThis retrospective study analyzed 1,465 patients with primary resectable breast cancer treated between 1979 and 1996. HOTAIR expression was measured in fresh frozen primary tumor tissue samples using qRT-PCR. Clinicopathological data were collected according to standardized criteria. Statistical analyses included non-parametric tests, logistic and Cox proportional hazards regression, and Kaplan-Meier curves and log-rank tests for survival outcomes (metastasis-free survival (MFS), progression-free survival (PFS), overall survival (OS)). Two-sided p-values < 0.05 were considered statistically significant.
resultsHOTAIR and EZH2 expression were both significantly associated with ER and HER2 status, and EZH2 also with age, histological features, and PR status. In 270 ER+/HER2- patients who received tamoxifen as first line treatment, higher expression of each HOTAIR and EZH2 were significantly associated with PFS, meanwhile, the combination of these two associated more strongly with PFS. In treatment-naïve lymph node-negative patients with ER+/HER2- tumors, higher HOTAIR expression was associated with worse MFS and OS with the tertile threshold.
conclusionThis study suggests that HOTAIR may have predictive value for tamoxifen resistance in ER+/HER2 − breast cancer, both independently and in combination with EZH2. Our findings further indicate that HOTAIR could potentially serve as a prognostic biomarker in this subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.